Proudly Canadian

Pr Vyxeos®

daunorubicin and cytarabine liposome for injection

44 mg / 100 mg

Dose Guide



PrVYXEOS® (daunorubicin and cytarabine liposome for injection) is indicated for the treatment of adults with newly diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).[1]

PREPARATION[1]

Calculate VYXEOS dose based on patient's BSA and determine the number of vials required.

Remove the vials of VYXEOS from the refrigerator and **equilibrate** at room temperature for 30 minutes.

DO NOT HEAT

Reconstitute each vial with 19 mL of sterile water for injections using a 20 mL sterile syringe and start a 5-minute timer immediately. **Carefully swirl the contents** of the vial for 5 minutes while gently inverting the vial every 30 seconds.

Rest for 15 minutes after reconstitution. If the reconstituted product is not immediately diluted into an infusion bag, **store** in a refrigerator (2°C to 8°C) for up to 4 hours.

DO NOT VORTEX OR SHAKE VIGOROUSLY

Gently invert each vial 5 times prior to withdrawing the concentrate for dilution.

Scan to watch how to properly prepare and reconstitute VYXEOS

Aseptically withdraw the calculated volume of reconstituted VYXEOS from the vial(s) with a sterile syringe and transfer it to an infusion bag containing 500 mL of sodium chloride 9 mg/mL (0.9%) solution for injection, or 5% glucose. **Discard any unused portions.**

Gently invert the bag to mix the solution. If the diluted infusion solution is not used immediately, store in a refrigerator (2°C to 8°C) for up to 4 hours.

BSA: Body surface area.

PERSONAL DOSING FOR YOUR PATIENTS

Surface area (m^2)	First induction (44/100 mg)/m^2		Second induction (44/100 mg)/m^2		Consolidation (29/65 mg)/m^2	
	Volume to withdraw per dose (mL)	Number of vials per course	Volume to withdraw per dose (mL)*	Number of vials per course	Volume to withdraw per dose (mL)†	Number of vials per course
1.3	26.0	6	26.0	4	17.1	2
1.4	28.0	6	28.0	4	18.5	2
1.5	30.0	6	30.0	4	19.8	2
1.6	32.0	6	32.0	4	21.1	4
1.7	34.0	6	34.0	4	22.4	4
1.8	36.0	6	36.0	4	23.7	4
1.9	38.0	6	38.0	4	25.0	4
2.0	40.0	6	40.0	4	26.4	4
2.1	42.0	9	42.0	6	27.7	4
2.2	44.0	9	44.0	6	29.0	4
2.3	46.0	9	46.0	6	30.3	4
2.4	48.0	9	48.0	6	31.6	4
2.5	50.0	9	50.0	6	33.0	4
2.6	52.0	9	52.0	6	34.3	4
2.7	54.0	9	54.0	6	35.6	4

$$\frac{\text{Dose of daunorubicin (mg/m}^2\text{) x patient's BSA (m}^2\text{)}}{\text{2.2 mg/mL}} = \text{mL volume required}$$

Missed a dose?

If a planned dose of VYXEOS is missed, administer the dose as soon as possible and adjust the dosing schedule accordingly with treatment interval maintained.[1]

*In patients not achieving a response, start 2 to 5 weeks after first induction.
†5 to 8 weeks after the start of last induction.

VYXEOS CAN BE ADMINISTERED FOR BOTH INDUCTION AND CONSOLIDATION IN ADULT PATIENTS WITH HIGH-RISK AML[1]*

INDUCTION CYCLES **CONSOLIDATION CYCLES**

Treatment should be continued as long as patients continue to benefit or until disease progression, up to a maximum of 2 courses for induction and consolidation each.[1]

After the first induction, subsequent induction courses may be:[1]

- Administered after 2–5 weeks in patients who do not achieve remission and show no unacceptable toxicity
- Required for some patients after bone marrow evaluation

After the start of the last induction course, subsequent consolidation courses may be:[1]

- Administered within 5–8 weeks in patients who do not show disease progression or unacceptable toxicity

Prior to initiating each cycle of induction and consolidation, assessment for cardiac, renal and hepatic function is recommended.[1]

*High-risk AML defined as t-AML or AML-MRC.

90 minutes VYXEOS HAS A 90-MINUTE INFUSION TIME[1]

Designed to reduce the infusion time for your patients with high-risk AML[2]*



Recommended dosing schedule for VYXEOS[1]

FIRST INDUCTION

Days 1 3 5

Daunorubicin 44 mg/m² and cytarabine 100 mg/m²

SECOND INDUCTION + CONSOLIDATION

Days 1 3

Second induction: Daunorubicin 44 mg/m² and cytarabine 100 mg/m²

Consolidation: Daunorubicin 29 mg/m² and cytarabine 65 mg/m²

Adapted from the VYXEOS Product Monograph.

Pr Vyxeos®
daunorubicin and cytarabine liposome for injection
44 mg / 100 mg

*High-risk AML defined as t-AML or AML-MRC.

Recommended dose adjustments for patients with symptoms of hypersensitivity[1]

Severity of symptoms	Recommended dose adjustment
Mild*	• Stop treatment and monitor patient, including vital signs • Slowly resume treatment once symptoms resolve at half the rate of infusion and consider intravenous antihistamines and/or corticosteroids
Moderate	• Do not re-initiate infusion
Severe or life-threatening	• Permanently discontinue treatment with VYXEOS

Adapted from the VYXEOS Product Monograph.

For more information:

Consult the Product Monograph at: www.jazzpharma.com for contraindications, warnings, precautions, adverse reactions, interactions, dosing and conditions of clinical use.

The Product Monograph is also available by calling our medical department at: 1-800-520-5568.

Further information for healthcare professionals can be found at www.vyxeos.ca

*Mild symptoms may include mild flushing, rash, pruritus.

REFERENCES: 1. Current VYXEOS® Product Monograph, Jazz Pharmaceuticals Canada, Inc.
2. Mayer LD, Tardi P, Louie AC. CPX-351: a nanoscale liposomal co-formulation of daunorubicin and cytarabine with unique biodistribution and tumor cell uptake properties. *Int J Nanomedicine* 2019;14:3819–3830.

CA-VYX-2300016

Jazz Pharmaceuticals®

Pr Vyxeos®
daunorubicin and cytarabine liposome for injection
44 mg / 100 mg